eFFECTOR Therapeutics

Update in progress

EFTR (OTC Markets OTCPK)

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company developing selective translation regulator inhibitors for cancer. Its lead candidate, Zotatifin, inhibits eIF4A and is in a Phase 1/2 trial for solid tumors, having completed a Phase 2 study in ER+ breast cancer when used with fulvestrant and abemaciclib. Tomivosertib, an oral MNK inhibitor, is in a Phase 2b trial for metastatic non-small cell lung cancer. The company has a Pfizer collaboration on eIF4E. Founded in 2012 and based in Solana Beach, California.